TearLab Corporation   Report issue

For profit
Founded: San Diego CA United States (2003)
Status: No NME R&D (2003)

Organization Overview

First Clinical Trial
2015
NCT02417116
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Other Trials (1)

icosapent ethyl (vascepa) (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1